Novacyt launches product to tell difference between COVID-19 and winter flu

Clinical diagnostics company Novacyt - one of many healthcare companies whose shares have surged during the pandemic - announced on Thursday a new product to allow people to differentiate the COVID-19 virus from common winter diseases.

PARIS, Aug 27 (Reuters) - Clinical diagnostics company Novacyt ALNOV.PA, NCYT.L - one of many healthcare companies whose shares have surged during the pandemic - announced on Thursday a new product to allow people to differentiate the COVID-19 virus from common winter diseases.

Novacyt said its new 'Winterplex' test panel includes two gene targets specific to COVID-19, as well as gene targets for influenza A&B and respiratory syncytial virus (RSV).

"We believe Winterplex™ is one of the world’s first approved respiratory test panels that can differentiate between COVID-19 and other common respiratory diseases," Novacyt CEO Graham Mullis said.

(Reporting by Sudip Kar-Gupta; editing by Jason Neely)

((sudip.kargupta@thomsonreuters.com; +33 1 49 49 53 84;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More